Aaron John

TL;DR: The interplay between oxygen status adjustment and the innate immune response in humans in vivo has not been investigated and hypoxia and hyperoxia could be cheap, non-pharmacological,non-invasive treatment modalities to modulate inflammatory conditions.

TL;DR: It is demonstrated that short-term hypoxia dampens the systemic pro-inflammatory cytokine response through enhanced purinergic signaling in mice and men and may contribute to outcome and provide leads for immunomodulatory treatment strategies for critically ill patients.

TL;DR: It is demonstrated that, in the absence of systemic inflammation, short-term hyperoxia does not result in increased levels of inflammatory cytokines in both mice and healthy volunteers, and expectations of using it as an immunomodulatory treatment strategy are tempered.

TL;DR: Proof of concept that lexaptepid achieves clinically relevant hepcidin inhibition enabling investigations in the treatment of anemia of inflammation is delivered, delivering proof of concept for the prevention of serum iron decrease during experimental human endotoxemia.